Psychopharmacology Collection

Section Editor: Laura G. Leahy, DrNP, APRN, PMH-CNS/FNP, BC

Published monthly, Psychopharmacology articles explore psychotherapeutic issues and agents in clinical practice.

From Immediate Release to Long Acting Drug Delivery Systems: What Do They Mean and Why Do They Matter?
Laura G. Leahy, DrNP, APRN, PMH-CNS/FNP, BC
May 2017

Premenstrual Exacerbations: Achieving Stability All Month, Every Month
Laura G. Leahy, DrNP, APRN, PMH-CNS/FNP, BC
April 2017

Genetic Testing for Psychopharmacology: Is It Ready for Prime Time?

Laura G. Leahy, DrNP, APRN, PMH-CNS/FNP, BC
March 2017

Off-Label Prescribing and Polypharmacy: Minimizing the Risks
Laura G. Leahy, DrNP, APRN, PMH-CNS/FNP, BC
February 2017

The Opioid Epidemic: What Does it Mean for Nurses?
Laura G. Leahy, DrNP, APRN, PMH-CNS/FNP, BC
January 2017

Hey Mister Tambourine Man, Play a Drug for Me: Music as Medication
Robert H. Howland, MD
December 2016

Deprescribing to Reduce Medication Use: Will This Help Your Patient?
Robert H. Howland, MD
November 2016

Methylene Blue: The Long and Winding Road From Stain to Brain: Part 2
Robert H. Howland, MD
October 2016

Methylene Blue: The Long and Winding Road from Stain to Brain: Part 1
Robert H. Howland, MD
September 2016

Antidepressant, Antipsychotic, and Hallucinogen Drugs for the Treatment of Psychiatric Disorders: A Convergence at the Serotonin-2A Receptor
Robert H. Howland, MD
July 2016

Pimavanserin: An Inverse Agonist Antipsychotic Drug
Robert H. Howland, MD
June 2016

Oxazepam for the Treatment of Substance Abuse and Depression: Is it Appropriate?
Robert H. Howland, MD
May 2016

Safety and Abuse Liability of Oxazepam: Is This Benzodiazepine Drug Underutilized?
Robert H. Howland, MD
April 2016

Can Declining Rates of Dementia Be Explained by the Increased and Widespread Use of Psychotropic Medications?
Robert H. Howland, MD
March 2016

Antidepressant Drugs and the Risk of Intracranial Bleeding: Parsing an Observational Study
Robert H. Howland, MD
February 2016

Trifluoperazine: A Sprightly Old Drug
Robert H. Howland, MD
January 2016

A Question About the Safety of Buprenorphine/Naloxone and Benzodiazepine Drugs
Robert H. Howland, MD
December 2015

Buspirone: Back to the Future
Robert H. Howland, MD
November 2015

Can a Bug in the Gut Act Like a Drug in the Brain?
Robert H. Howland, MD
October 2015

Deuterated Drugs
Robert H. Howland, MD
September 2015 

"I Want a New Drug": Exercise as a Pharmacological Therapy
Robert H. Howland, MD
August 2015

Do Psychiatric Medications Cause More Harm Than Good?
Robert H. Howland, MD
July 2015 

Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain
Robert H. Howland, MD
June 2015

“Evidence” and the Treatment of Alcohol Use Disorder
Robert H. Howland, MD
May 2015 

Brexpiprazole: Another Multipurpose Antipsychotic Drug?
Robert H. Howland, MD
April 2015

Aspergillus, Angiogenesis, and Obesity: The Story Behind Beloranib
Robert H. Howland, MD
March 2015

Psychiatric Medications and Sudden Cardiac Death: Putting the Risk in Perspective
Robert H. Howland, MD
February 2015

Odds and Ends in Psychopharmacology From the Past 10 Years
Robert H. Howland, MD
January 2015

A Proposed System for Classifying Psychotropic Drugs
Robert H. Howland, MD
December 2014

Pharmacogenetic Testing in Psychiatry: Not (Quite) Ready for Primetime
Robert H. Howland, MD
November 2014

Suvorexant: A Novel Therapy for the Treatment of Insomnia
Robert H. Howland, MD
October 2014

Atypical Antipsychotics Are Not All Alike: Side Effects and Risk Assessment
Robert H. Howland, MD
September 2014

Psychotropic Medication Use: What Will It Do To My Liver?
Robert H. Howland, MD
August 2014

Down the Hatch: Is Prescribing Medication Really That Simple?
Robert H. Howland, MD
July 2014

The Comparative Cardiac Effects of Haloperidol and Quetiapine: Parsing a Review
Robert H. Howland, MD
June 2014

Delirium and Its Prevention with Melatonergic Drugs
Robert H. Howland, MD
May 2014

Update on Deep Brain Stimulation
Robert H. Howland, MD
April 2014 

New Developments with Vagus Nerve Stimulation Therapy
Robert H. Howland, MD
March 2014

Gabapentin for Substance Use Disorders: Is it Safe and Appropriate?
Robert H. Howland, MD
February 2014

Gabapentin: Can It Be Misused?
Robert H. Howland, MD
January 2014

Gabapentin for the Treatment of Substance Use Disorders
Robert H. Howland, MD
December 2013

Concern for Truth: Driving Defensively When Confronting a Zombie Epidemic
Robert H. Howland, MD
November 2013

More on Antidepressant Drugs and Infectious Disease
Robert H. Howland, MD
October 2013

A "Glucose Eater" Drug as a Therapeutic Agent in Psychiatry
Robert H. Howland, MD
September 2013

Efficacy of Quetiapine Off-Label Uses: Data Synthesis
Adam C. Carney, RN, BSN
August 2013

Antidepressant Drugs and Infectious Disease
Robert H. Howland, MD
July 2013

Mifepristone as a Therapeutic Agent in Psychiatry
Robert H. Howland, MD
June 2013

Therapies for Obesity and Medication-Associated Weight Gain
Robert H. Howland, MD
May 2013

Diagnostic Classification Past, Present, and Future: Implications for Pharmacotherapy
Robert H. Howland, MD
April 2013

Adherence Challenges and Long-Acting Injectable Antipsychotic Treatment in Patients with Schizophrenia
N. Kirk Morton, RN, BSN; Donna Zubek, BSN, MBA
March 2013

Antidepressant Medication and Pregnancy: Time for Randomized Controlled Trials
Robert H. Howland, MD
February 2013

Ketamine for the Treatment of Depression
Robert H. Howland, MD
January 2013

Future Prospects for Pharmacogenetics in the Quest for Personalized Medicine
Robert H. Howland, MD
December 2012

Where Are We Today with Personalized Medicine?
Robert H. Howland, MD
November 2012

Baclofen for the Treatment of Alcohol Dependence
Robert H. Howland, MD
October 2012

Off-Label Medication Use
Robert H. Howland, MD
September 2012

PRN Psychotropic Medication and Acute Mental Health Nursing: Reviewing the Evidence
Luke Molloy, RPN, DipNS, BN(Hons.), MNLead, MN(Hons.); John Field, RN, DipNE, BLegSt, GCertManag, PhD; Paul Beckett, RMN, DipHE, BSc(Hons.), MN; Douglas Holmes
August 2012

Questions to Ask When Selecting Medication
Robert H. Howland, MD
July 2012

Dietary Supplement Drug Therapies for Depression
Robert H. Howland, MD
June 2012

The Challenges of Clinical Psychopharmacological Management
Robert H. Howland, MD
May 2012

A Question About the Potential Cardiac Toxicity of Escitalopram
Robert H. Howland, MD
April 2012

Effective Medication Management
Robert H. Howland, MD
March 2012

The Use of Dopaminergic and Stimulant Drugs for the Treatment of Depression
Robert H. Howland, MD
February 2012

Now Take a Deep Breath: Inhaled Loxapine for the Treatment of Acute Agitation
Robert H. Howland, MD
January 2012

A Critical Evaluation of the Cardiac Toxicity of Citalopram: Part 2
Robert H. Howland, MD
December 2011

A Critical Evaluation of the Cardiac Toxicity of Citalopram: Part 1
Robert H. Howland, MD
November 2011

Understanding and Assessing Adverse Drug Reactions
Robert H. Howland, MD
October 2011

Publication Bias and Outcome Reporting Bias: Agomelatine as a Case Example
Robert H. Howland, MD
September 2011

What You See Depends on Where You're Looking and How You Look at It: Publication Bias and Outcome Reporting Bias
Robert H. Howland, MD
August 2011

Drug Therapies for Tardive Dyskinesia: Part 2
Robert H. Howland, MD
July 2011

Drug Therapies for Tardive Dyskinesia: Part 1
Robert H. Howland, MD
June 2011

Alternative Drug Therapies for Dementia
Robert H. Howland, MD
May 2011

Update on Newer Antipsychotic Drugs
Robert H. Howland, MD
April 2011

Vilazodone: Another Novel Atypical Antidepressant Agent
Robert H. Howland, MD
March 2011

Vitamin D and Depression
Robert H. Howland, MD
February 2011

Sleep Interventions for the Treatment of Depression
Robert H. Howland, MD
January 2011

Use of Endocrine Hormones for Treating Depression
Robert H. Howland, MD
December 2010

Update on St. John's Wort
Robert H. Howland, MD
November 2010

Serendipity and Psychopharmacology
Robert H. Howland, MD
October 2010

Potential Adverse Effects of Discontinuing Psychotropic Drugs: Part 4: Benzodiazepine, Glutamate, Opioid, and Stimulant Drugs
Robert H. Howland, MD
September 2010

Potential Adverse Effects of Discontinuing Psychotropic Drugs: Part 3: Antipsychotic, Dopaminergic, and Mood-Stabilizing Drugs
Robert H. Howland, MD
August 2010

Potential Adverse Effects of Discontinuing Psychotropic Drugs: Part 2: Antidepressant Drugs
Robert H. Howland, MD
July 2010

Potential Adverse Effects of Discontinuing Psychotropic Drugs: Part 1: Adrenergic, Cholinergic, and Histamine Drugs
Robert H. Howland, MD
June 2010

The Diverse Clinical Uses of Opioid Receptor Drugs
Robert H. Howland, MD
May 2010

Drug Therapies for Cognitive Impairment and Dementia
Robert H. Howland, MD
April 2010

Are Generic Medications Safe and Effective?
Robert H. Howland, MD
March 2010

When is a "Generic" Medication Not Really a Generic? Confusion About Medication Products Containing the Same Active Ingredient
Robert H. Howland, MD
February 2010

Evaluating the Bioavailability and Bioequivalence of Generic Medications
Robert H. Howland, MD
January 2010

What Makes a Generic Medication Generic?
Robert H. Howland, MD
December 2009

Prescribing Psychotropic Medications for Elderly Patients
Robert H. Howland, MD
November 2009

Effects of Aging on Pharmacokinetic and Pharmacodynamic Drug Processes
Robert H. Howland, MD
October 2009

Medication Holidays
Robert H. Howland, MD
September 2009

Clinical Implications of Chirality and Stereochemistry in Psychopharmacology
Robert H. Howland, MD
August 2009

Understanding Chirality and Stereochemistry: Three-Dimensional Psychopharmacology
Robert H. Howland, MD
July 2009

The Antidepressant Effects of Anticholinergic Drugs
Robert H. Howland, MD
June 2009

Prescribing Psychotropic Medications During Pregnancy and Lactation: Principles and Guidelines
Robert H. Howland, MD
May 2009

Categorizing the Safety of Medications During Pregnancy and Lactation
Robert H. Howland, MD
April 2009

Evaluating the Safety of Medications During Pregnancy and Lactation
Robert H. Howland, MD
March 2009

What Should Patients Be Told About Their Medications?
Robert H. Howland, MD
February 2009

Somatic Therapies for Seasonal Affective Disorder
Robert H. Howland, MD
January 2009

Understanding the Clinical Profile of a Drug on the Basis of Its Pharmacology: Mirtazapine as an Example
Robert H. Howland, MD
December 2008

Risks and Benefits of Antipsychotic Drugs in Elderly Patients With Dementia
Robert H. Howland, MD
November 2008

Sequenced Treatment Alternatives to Relieve Depression (STAR*D): Part 2: Study Outcomes
Robert H. Howland, MD
October 2008

Sequenced Treatment Alternatives to Relieve Depression (STAR*D): Part 1: Study Design
Robert H. Howland, MD
September 2008

Lisdexamfetamine: A Prodrug Stimulant for ADHD
Robert H. Howland, MD
August 2008

Pharmacotherapy for Psychotropic Drug-Related Weight Gain
Robert H. Howland, MD
July 2008

Understanding the Placebo Effect: Part 2: Underlying Psychological & Neurobiological Processes
Robert H. Howland, MD
June 2008

Understanding the Placebo Effect: Part 1: Placebo Use in Clinical Trials
Robert H. Howland, MD
May 2008

Neurosurgical Approaches to Therapeutic Brain Stimulation For Treatment-Resistant Depression
Robert H. Howland, MD
April 2008

How Are Drugs Approved? Part 3. The Stage of Drug Development
Robert H. Howland, MD
March 2008

How Are Drugs Approved? Part 2: Ethical Foundations of Clinical Research
Robert H. Howland, MD
February 2008

How Are Drugs Approved? Part 1: The Evolution of the Food and Drug Administration
Robert H. Howland, MD
January 2008

Agomelatine: A Novel Atypical Antidepressant
Robert H. Howland, MD
December 2007

Limitations of Evidence in the Practice of Evidence-Based Medicine
Robert H. Howland, MD
November 2007

Cytochrome P450 Testing for Better Psychiatric Care
Elizabeth L. Pestka, MS, APRN, BC, APNG; Ann M. Hale, BSN, RN; Bonnie L. Johnson, BAN, RN; Joy L. Lee, BAN, RN; Kathleen A. Poppe, MS, RN
October 2007

Medication Adherence
Robert H. Howland, MD
September 2007

Lithium: Underappreciated and Underused?
Robert H. Howland, MD
August 2007

Antidepressants & Suicide: Putting the Risk in Perspective
Robert H. Howland, MD
July 2007

Pharmacotherapy in Personality Disorders
Robert H. Howland, MD
June 2007

Paliperidone Extended-Release Tablets: A New Atypical Antipsychotic
Robert H. Howland, MD
May 2007

SSRIs & the Risk of Abnormal Bleeding
Roy R. Reeves, DO, PhD; P. Melonee Wise, RPH; Sera K. Cox, MD
April 2007

Unusual & Serious Adverse Effects of SSRIs: Recognition & Management
Robert H. Howland, MD
March 2007

Managing Common Side Effects of SSRIs
Robert H. Howland, MD
February 2007

Glutamate-Modulating Drugs & the Treatment of Mental Disorders
Robert H. Howland, MD
January 2007

Pharmacotherapy for Psychotic Depression
Robert H. Howland, MD
December 2006

Pharmacotherapy Strategies for Treatment-Resistant Depression
Robert H. Howland, MD
November 2006

Electroencephalography Technology for Predicting Response to Antidepressant Medications
Robert H. Howland, MD
October 2006

Vagus Nerve Stimulation for Depression and Other Neuropsychiatric Disorders
Robert H. Howland, MD
September 2006

What is Vagus Nerve Stimulation?
Robert H. Howland, MD
August 2006

Transdermal Selegiline: A Novel MAOI Formulation for Depression
Robert H. Howland, MD
July 2006

MAOI Antidepressant Drugs
Robert H. Howland, MD
June 2006

Challenges in the Diagnosis & Treatment of Bipolar Depression: Part 2: Treatment Options
Robert H. Howland, MD
May 2006

Challenges in the Diagnosis & Treatment of Bipolar Depression: Part 1: Assessment
Robert H. Howland, MD
April 2006

Principles and Practice of Polypharmacotherapy
Robert H. Howland, MD
March 2006

Personalized Drug Therapy with Pharmacogenetics: Part 2: Pharmacodynamics
Robert H. Howland, MD
February 2006

Personalized Drug Therapy with Pharmacogenetics: Part 1: Pharmacokinetics
Robert H. Howland, MD
January 2006

Advertisement
Advertisement